Teladoc (NYSE: TDOC) stock got crushed in Wednesday’s trading session. The online healthcare specialist’s share price ended the day’s trading down 23.7%, according to data from S&P Global Market Intelligence.
Teladoc released its Q4 results after the market closed yesterday and actually posted a loss for the period that was significantly smaller than expected. But the company’s sales performance for the quarter missed Wall Street’s target, and management issued disappointing forward guidance. The stock is now down roughly 49% over the last year, and it trades 95% off its peak level.
Teladoc’s growth has slowed to a crawl
Teladoc posted a per-share loss of $0.17 on sales of $660.53 million in the fourth quarter. Meanwhile, the average analyst estimate had called for the business to post a loss per share of $0.24 on revenue of roughly $670.1 million.
Teladoc’s sales increased just 3.6% year over year in Q4, marking another quarter of substantial deceleration for sales growth. For reference, the company’s revenue increased 15% year over year in Q4 2022 and 45% year over year in Q4 2021 thanks to pandemic-related tailwinds and the company’s acquisition of Livongo.
Unfortunately, Teladoc shelled out roughly $18.5 billion to acquire Livongo in 2020, and the combined company’s sales growth has now nearly stalled. Teladoc has already taken massive write-offs related to the Livongo acquisition, and the company’s overall health and outlook are looking increasingly gloomy on the heels of its Q4 report.
What comes next for Teladoc?
For the first quarter of this year, Teladoc is guiding for sales between $630 million and $645 million. At the midpoint of the guidance range, that would mean posting sales growth of 1.3% year over year. The average Wall Street target had called for sales of $672.95 million.
On the earnings front, the company is guiding for a loss per share between $0.45 and $0.55. The average analyst estimate had called for a loss per share of $0.37. So even though Teladoc’s loss came in lower than expected in Q4, its guidance suggests that last quarter’s beat will more than be erased this quarter.
For the full-year period, management is targeting revenue between $2.635 million and $2.735 million. Meanwhile, the average analyst estimate had called for sales of $2.77 billion. If Teladoc were to hit the midpoint of its sales guidance, revenue would be up roughly 3% annually. For reference, the business grew sales 8% annually in 2023.
All in all, there was very little to like in Teladoc’s Q4 report. With signs that growth will continue to slow and indications that losses may come in significantly higher than previously anticipated, it’s not surprising that shares cratered today.
Should you invest $1,000 in Teladoc Health right now?
Before you buy stock in Teladoc Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teladoc Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 20, 2024
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool has a disclosure policy.
Why Teladoc Stock Crashed Today was originally published by The Motley Fool
Signup bonus from
